Search

DLL3 Targeting CAR-T Cell Therapy Patent Granted to Allogene Therapeutics

The USPTO granted Patent US12606623B2 to Allogene Therapeutics, Inc. covering DLL3 binding agents and chimeric antigen receptors (CARs) for use in immune cell therapies, specifically CAR-T cells. The patent includes 26 claims and covers methods of making and using DLL3-specific CARs. This grant establishes exclusive IP rights for the assignee in the specified therapeutic domain.

Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic CAR T Cell Persistence

The European Patent Office published patent application EP4355358A1 on April 8, 2026, filed by Allogene Therapeutics, Inc. The invention covers methods for selectively targeting host CD70+ alloreactive cells to enhance persistence of allogeneic CAR-T cells for therapeutic use. The patent is designated across multiple European member states including Germany, France, and the United Kingdom.